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Abstract
Background: SOX2 is a key gene implicated in maintaining the stemness of embryonic and adult stem cells. SOX2
appears to re-activate in several human cancers including glioblastoma multiforme (GBM), however, the detailed
response program of SOX2 in GBM has not yet been defined.
Results: We show that knockdown of the SOX2 gene in LN229 GBM cells reduces cell proliferation and colony
formation. We then comprehensively characterize the SOX2 response program by an integrated analysis using
several advanced genomic technologies including ChIP-seq, microarray profiling, and microRNA sequencing. Using
ChIP-seq technology, we identified 4883 SOX2 binding regions in the GBM cancer genome. SOX2 binding regions
contain the consensus sequence wwTGnwTw that occurred 3931 instances in 2312 SOX2 binding regions.
Microarray analysis identified 489 genes whose expression altered in response to SOX2 knockdown. Interesting
findings include that SOX2 regulates the expression of SOX family proteins SOX1 and SOX18, and that SOX2 down
regulates BEX1 (brain expressed X-linked 1) and BEX2 (brain expressed X-linked 2), two genes with tumor
suppressor activity in GBM. Using next generation sequencing, we identified 105 precursor microRNAs
(corresponding to 95 mature miRNAs) regulated by SOX2, including down regulation of miR-143, -145, -253-5p and
miR-452. We also show that miR-145 and SOX2 form a double negative feedback loop in GBM cells, potentially
creating a bistable system in GBM cells.
Conclusions: We present an integrated dataset of ChIP-seq, expression microarrays and microRNA sequencing
representing the SOX2 response program in LN229 GBM cells. The insights gained from our integrated analysis
further our understanding of the potential actions of SOX2 in carcinogenesis and serves as a useful resource for the
research community.
Background
The SOX (SRY-like HMG box) gene family represents a
family of transcriptional factors characterized by the
presence of a homologous sequence called the HMG
(high mobility group) box. The HMG box is a DNA
binding domain that is highly conserved throughout
eukaryotic species. So far, twenty SOX genes have been
identified in humans and mice and they can be divided
into 10 subgroups on the basis of sequence similarity
and genomic organization [1,2]. SOX genes bind to the
minor groove in DNA to control diverse developmental
processes [3].
SOX2, one of the key members of the SOX family
gene, is highly expressed in embryonic stem cells [4].
Recently, Takahashi et al. showed that SOX2 is a key
transcription factor, in conjunction with KLF4, OCT4
and c-Myc, whose over expression can induce pluripo-
tency in both mice and human somatic cells [5,6]. SOX2
is one of the four factors (OCT4, SOX2, NANOG, and
LIN28) that Yu et al. used to reprogram human somatic
cells to pluripotent stem cells that exhibit the essential
characteristics of embryonic stem (ES) cells [7]. SOX2 is
one of the two factors (SOX2 and OCT4)t h a tw e r es u f -
ficient to generate induced pluripotent stem cells from
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conferring stemness of cells, the target genes for SOX2
in mouse embryonic stem cells were defined using
ChIP-seq technology [9].
SOX2 has also been implicated in several cancers includ-
ing gastric cancer [10,11], breast cancer [12,13], pancreatic
cancer [14], pulmonary non-small cell and neuroendocrine
carcinomas [15]. In addition, SOX2 was identified to be a
prognostic marker for human esophageal squamous cell
carcinoma [16] and rectal cancer [17]. Schmitz et al.
found that SOX2 is over expressed in malignant glioma
while displaying minimal expression in normal tissues
[18]. More recently, Gangemi et al. showed that silencing
of the SOX2 in freshly derived glioblastoma tumor-initiat-
ing cells (TICs) stopped proliferation and the resulting
cells lost tumorigenicity in immunodeficient mice [19].
Ikushima et al. showed that inhibition of TGF-beta signal-
ing drastically deprived tumorigenicity of glioma-initiating
cells (GICs) by promoting their differentiation, and that
these effects were attenuated in GICs transduced with
SOX2 or SOX4 [20]. Taking together, these data suggested
that SOX2 is also a key gene in maintaining the stemness
of glioma stem cells.
Given that SOX2 is predominantly expressed in
embryonic and adult stems cells, including neural pro-
genitor cells, and re-activates in cancers, including
malignant gliomas, we hypothesized that the re-activa-
tion program of SOX2 m a yp l a ya ni m p o r t a n tr o l ei n
the carcinogenesis and maintenance of GBM. Although
the SOX2 response program in mouse stem cells was
previously defined [9], the re-activation program in
cancers such as GBM has not yet been defined. Using
ChIP-seq technology, we conducted a genome-wide tar-
get identification for SOX2 binding in GBM cells. We
generated mRNA expression profiles using the Applied
Biosystems’ microarray platform and microRNA expres-
sion profiles using next-generation sequencing after
knockdown of SOX2 expression in GBM cells. An inte-
grated analysis of these data reveals key response pro-
grams that potentially play important roles in GBM.
Results
SOX2 affects colony formation and cell proliferation in
GBM
We previously completed massively parallel signature
sequencing (MPSS) and identified SOX2 as significantly
over expressed in GBM tissues compared to normal
brain tissues [21]. We identified two MPSS tags that
correspond to different polyadenylated isoform, and
both are up-regulated in GBM tissues compared to nor-
mal brain tissues [21]. Our data is consistent with the
observation that SOX2 is widely expressed in gliomas
including glioblastomas but not in normal brains except
for in ependymal layers [22].
To assess the functional consequences of SOX2,w e
knocked down the SOX2 gene by siRNAs in the GBM
cell line LN229 using SOX2 SiRNAs (Ambion Inc.). As
shown in Figure 1A, we were able to knockdown SOX2
almost completely using either of the pre-designed
SOX2 siRNAs (s13295 and s13296) from Ambion Inc.
(Now Applied Biosystems Inc.).
Knockdown of the SOX2 gene in LN229 cells signifi-
cantly reduced the numbers of colonies formed as
shown in Figure 1B. In three replicate experiments, the
colony numbers for the MOCK-knockdown cells were
53.3 (STDEV = 2.5) while that for the SOX2 knockdown
were 24.7 (STDEV = 2.5) (T-test P = 0.00015, 2 tails,
type 2). Furthermore, knockdown of SOX2 in LN229
cells reduced the numbers of cells, reaching statistical
significance at day four (T-test P < 0.001) and further at
day six (T-test P = 1.45E-06) by MTT assays (Figure 1C).
Global identification of SOX2 binding sites in GBM cells
by ChIP-seq analysis
In order to understand the genome-wide binding pat-
terns of SOX2, we applied ChIP-seq technology, which
is a novel approach for identifying transcription factor
binding sites genome-wide [23,24]. We performed repli-
cate SOX2 ChIP and IgG ChIP. After sequencing analy-
sis, we obtained a total of 1,139,535 and 638,279
sequence tags respectively for SOX2 and IgG that can
be mapped uniquely to the human genome allowing two
mismatches.
Using the SISSRs (Site Identification from Short
Sequence Reads) ChIP-seq analysis program [25], we
identified a total of 4,883 SOX2 binding regions with a
P value < 0.01 using IgG control ChIP-seq data as the
negative control (Additional File 1). We randomly
picked 15 genes for which the promoter regions are
enriched for the SOX2 IP, and we were able to confirm
all 15 genes to be enriched in the SOX2 IP DNAs com-
pared to the IgG-IP DNAs using real time quantitative
PCR (Figure 2A), suggesting that the false positive rate
is negligible in our dataset.
There are 4714 SOX2 binding regions that can be
mapped to TSS (transcription start site) of 3420 known
genes. We calculated the distance of the SOX2 binding
regions to TSS (transcription start sites) and then tabu-
lated the frequency across the distance intervals before
TSS and after TSS. Figure 2B shows that the peak of the
SOX2 binding regions is around the TSS sites. We
found that about 13% SOX2 (605 of 4714) binding
regions are mapped within 8 kb of TSS (Figure 2B), and
about 25% (1161 binding regions) are mapped > 8 kb 5’
distal to the TSS. The rest mapped to > 8 kb down-
stream of TSS start sites of genes.
To understand the function of the SOX2 binding
genes, we performed a GO analysis using the GO miner
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enriched GO terms include GO:0005096 GTPase activa-
tor activity, GO:0022843 voltage-gated cation channel
activity, GO:0008066 glutamate receptor activity,
GO:0005070 SH3 SH2 adaptor activity, GO:0005001
transmembrane receptor protein tyrosine phosphatase
activity (Table 1). It should be pointed that expression
Figure 1 Functional analysis of SOX2 in GBM cells. (A) Western blot analysis showing the known down efficiency of SOX2 siRNAs (s13295 and
s13296). (B) Colony formation assays for SOX2 knockdown and mock control. (C). Cell proliferation assays for SOX2 knockdown and mock control.
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Page 3 of 17Figure 2 ChIP-seq analysis of SOX2 in GBM cells. Quantitative real time PCR for the confirmation of ChIP-seq peaks. Relative amount of PCR
products from SOX2-ChIP and IgG-ChIP were shown as bar graph with the amount of IgG-ChIP normalized to 1. Standard deviations were also
shown for SOX2-IP. (B) Histograms of SOX2 binding sites around annotated TSS (Transcription start sites) Frequencies of SOX2 island binding were
calculated every 10 kilobases (Y-axis). Relative distance to TSS is shown in X-axis, Negative and positive values indicate localization 5’ or 3’ to TSS
respectively. (C). A VENN diagram showing the overlaps of SOX2 targets among human GBM cells, human ES cells and mouse ES cells. (D). The
consensus sequence wwTGnwTw with log-likelihood score of 13920.71 identified by the MotifSampler program. The over represented sequences
were used as input for the Weblog program (http://weblogo.berkeley.edu/) [53] to display the consensus sequence graphically.
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Page 4 of 17of 196 of 792 genes with signal transducer activity,
(GO:0004871), 137 of 562 receptor genes (GO:0004872)
(among them, 101 of 410 transmembrane receptor
genes, GO: 0004888), and 92 of 365 kinase genes
(GO:0016301) (Table 1) was altered in response to
SOX2 knockdown.
Marson et al.a n dC h e net al. recently used ChIP-seq
to map binding sites of SOX2 and other key TFs in the
mouse ES cells [9,26]. Morsen et al.i d e n t i f i e d4 , 0 8 7
SOX2 binding sites corresponding to 2,884 genes based
o nt h ec r i t e r i at h a tab i n d i n gs i t ei sw i t h i n5 0k bo f
the TSS or TES (transcript end site). Chen et al.i d e n -
tified 4,526 SOX2 binding regions (from their Supple-
mentary Table 3) that could be assigned to 2,601 genes
o ft h eg e n eu s i n gt h es a m ec r i t e r i a .T h eu n i o no ft h e
two lists generated 4,380 genes. Interestingly, the over-
lapped genes between the two lists is 1105 genes
(25.2%) (Additional File 2). The difference could be
due to the use of different antibodies, Chen et al.u s e d
the SOX2 antibody (sc-17320, Santa Cruz Inc) while
Morson et al. used an affinity purified goat polyclonal
antibody (AF2018, R&D Systems), or differences in the
analysis pipeline and down stream analysis procedures
[9,26].
Using the homologene table for human and mouse
from NCBI (http://www.ncbi.nlm.nih.gov/homologene),
we compared the SOX2 targets that we identified in
LN229 cells with the SOX2 targets that were identified
in mouse ES cells [26]. We were able to identify 929
human homologues of 1105 mouse SOX2 binding genes
from Chen et al’s paper, and then were able to identify
233 unique genes (25%) (Additional File 1) that are
common to the SOX2 binding gene in the human GBM
cells (Figure. 2C). These suggest that there are common
sets of genes regulated by SOX2 in humans and mice,
and in ES cells and in cancer cells. However, we identi-
fied many SOX2 binding sites that are only present in
the glioblastoma cell line, suggesting that SOX2 targets
different pathways in the context of cancer cells.
Boyer et al. applied ChIP-chip technology to identify
OCT4, SOX2,a n dNANOG target genes in human
embryonic stem cells using a human promoter array
[27]. They identified 1,271 of the SOX2 binding promo-
ter regions for known protein-coding genes in human
ES cells. In LN229 cells, we found 258 unique genes
that overlapped with their data (Additional File 1 and
F i g u r e .2 C ) .A n a l y s i sw i t ht h eF i s h e r ’s Exact test (one
sided) revealed that the overlap is highly significant (P <
0.001). This suggests that while there is some conserva-
tion of the genes regulated by SOX2 in ES cells and
GBM cells, there are also differences in SOX2 binding
regions between the cells. The difference could be due
to several factors. First, there are differences in technol-
ogies used. The array designed by Boyer et al. covered
Table 1 GO terms that are enriched in SOX2 binding genes identified by ChIP-seq
GO CATEGORY TOTAL
GENES
Changed
Genes
Enrichment
folds
P value
(Log10)
FDR
GO:0005096_GTPase_activator_activity 60 27 2.39 -5.54 0.01
GO:0004871_signal_transducer_activity 792 196 1.31 -5.17 0.003333
GO:0060089_molecular_transducer_activity 792 196 1.31 -5.17 0.003333
GO:0060090_molecular_adaptor_activity 48 20 2.21 -3.69 0.0175
GO:0022843_voltage-gated_cation_channel_activity 66 25 2.01 -3.67 0.014
GO:0008066_glutamate_receptor_activity 20 11 2.92 -3.50 0.016667
GO:0004872_receptor_activity 562 137 1.29 -3.41 0.02
GO:0005070_SH3_SH2_adaptor_activity 43 18 2.22 -3.40 0.02
GO:0004672_protein_kinase_activity 278 75 1.43 -3.37 0.017778
GO:0005001_transmembrane_receptor_protein_tyrosine_phosphatase_activity 18 10 2.95 -3.27 0.019091
GO:0019198_transmembrane_receptor_protein_phosphatase_activity 18 10 2.95 -3.27 0.019091
GO:0005099_Ras_GTPase_activator_activity 28 13 2.47 -3.11 0.023333
GO:0030695_GTPase_regulator_activity 124 38 1.63 -3.02 0.023077
GO:0016301_kinase_activity 365 92 1.34 -2.92 0.027143
GO:0042805_actinin_binding 4 4
GO:0008092_cytoskeletal_protein_binding 164 47 1.52 -2.89 0.026667
GO:0016773_phosphotransferase_activity__alcohol_group_as_acceptor 326 83 1.35 -2.82 0.029375
GO:0004888_transmembrane_receptor_activity 410 101 1.31 -2.80 0.029412
GO:0005244_voltage-gated_ion_channel_activity 76 25 1.75 -2.63 0.035263
GO:0022832_voltage-gated_channel_activity 76 25 1.75 -2.63 0.035263
GO:0030674_protein_binding__bridging 58 20 1.83 -2.47 0.0455
Fang et al. BMC Genomics 2011, 12:11
http://www.biomedcentral.com/1471-2164/12/11
Page 5 of 17t h e- 8k bt o+ 2k br e g i o nr e l a t i v et oe a c ht r a n s c r i p t i o n
start site of 18,002 transcription start sites representing
17,917 unique genes. If a SOX2 binding region is outside
of the region covered by the printed oligos, or is not on
the array, it would be missed by ChIP-chip analysis.
However, the ChIP-seq technology is not limited by the
probes selected to be printed on a chip, and therefore
could identify SOX binding regions further upstream or
down stream of genes. Second, the SOX2 response pro-
gram could be different in different cells (i.e. GBM vs.
ES cells). It is possible that different SOX proteins inter-
act selectively with and regulate a unique repertoire of
target genes, and the selectivity is dependent on the
type of cell in which the protein is expressed.
To see whether they were unique functional classifica-
tion or over representation for the SOX2 targets in
GBM cells versus those in human ES cells, we compared
3162 unique SOX2 targets in GBM cells with 817
unique SOX2 targets in human ES cells using GSEA to
identify unique over represented GO terms in each set
of targets. We found that the unique SOX2 targets in
GBM cells were enriched for ion transport, receptor
activities, neuron differentiation neurogenesis, etc.
(Additional File 3), while the unique SOX2 targets in
human ES cells are enriched for macromolecular com-
plex, ion homeostasis, apoptotic program, ATPase activ-
ity, etc. (Additional File 4).
We were interested to see whether the genes related to
stemness and/or differentiation are SOX2 targets in GBM
cells. Using the molecular signature database (http://
www.broadinstitute.org/gsea/msigdb/index.jsp) at the
Broad Institute, we found that GO term GO:0045595
(REGULATION OF CELL DIFFERENTIATION) con-
sists of a compiled set of 59 genes related to differentia-
tion. In addition, Ben-Porath et al. curated a gene set
with 378 genes over expressed in human embryonic stem
cells according to 5 or more out of 20 profiling studies in
the Table S1 of their published paper [28]. We found
that 17 of 59 genes related to regulation of cell differen-
tiation were SOX2 targets in GBM cells including ACIN1
(apoptotic chromatin condensation inducer 1), BMPR1B
(bone morphogenetic protein receptor, type IB), ETS1
(V-ets erythroblastosis virus E26 oncogene homolog 1),
SHH (sonic hedgehog homolog, Drosophila), IGFBP3
(insulin-like growth factor binding protein 3) and
RUNX1 (Runt-related transcription factor 1) (Additional
File 5). In addition, 71 of 378 ES enriched genes were
SOX2 targets in GBM cells including CDC20 (cell divi-
sion cycle 20 homolog of S. cerevisiae), CHEK2 (CHK2
checkpoint homolog of S. pombe), FGF13 (fibroblast
growth factor 13), RFC3 [replication factor C (activator
1) 3, 38 kDa] and UTF1 (undifferentiated embryonic cell
transcription factor 1) (Additional File 6). However, we
did not find OCT4 and NANOG to be SOX2 targets in
GBM cells.
Identification of the DNA binding consensus and other
known TF binding sites in the SOX2 bound regions
To see whether the human SOX2 binding regions in
GBM cells have their own unique and enriched binding
motif, we used the MotifSampler program (http://bioin-
formatics.psb.ugent.be/webtools/plantcare/html/Motif_-
Sampler.html) to identify binding consensus sequences
enriched in the SOX2 binding regions that we identified.
We found a consensus sequence wwTGnwTw with a
very high log-likelihood score of 13920.71. The output
matrix for this consensus sequence is shown in Addi-
tional File 7, and there are 3931 instances of this motif
in 2312 SOX2 binding regions (Additional File 8). The
consensus logo is shown in Figure 2D.
We were curious whether known TFs could bind to
the SOX2 binding regions that we identified and act as
SOX2 cooperators for the regulation of gene expression.
In order to systematically search for potential bindings
of other transcription factors, we used the MotifScanner
program (http://bioinformatics.psb.ugent.be/webtools/
plantcare/html/Motif_Sampler.html) and scanned all TF
motif matrices (PWM databases) using the human tran-
scription factor subset of the Transfac professional 7.0.
Matched matrices with likelihood (LR) ratios of 500 or
higher were tabulated and frequencies calculated (Addi-
tional File 9). Among the top known TF matrices (Table
2) that were identified as co-occurred more than 10% of
the time with SOX2 in the SOX2-binding region are: the
O C Tf a m i l y ,t h eF O Xf a m i l y ,t h eH N Ff a m i l y ,t h e
GATA family and several other TF IRF1 (interferon reg-
ulatory factor 1), POU1F1 (POU class 1 homeobox 1),
TEF1 (TEAD1, TEA domain family member 1), AREB6
(ZEB1, zinc finger E-box binding homeobox 1) and GR
(glucocorticoid receptor, also named NR3C1, nuclear
receptor subfamily 3, group C, member 1).
POU1F1 is the POU class 1 homeobox 1. OCT family
TFs also contain POU domains. These suggest that
SOX2 and many POU domain proteins may act together
to control gene expression. SOX2 and OCT family TFs
such as OCT1 (POU2F1, POU class 2 homeobox 1) and
OCT3/4 (POU5F1, POU class 5 homeobox 1) are well
known to work synergistically in embryonic stem cells
[29,30]. Additionally, we identified novel transcriptional
factors in the SOX2 bound regions, including FOX (fork
head transcription factor) and HNF (hepatocyte nuclear
factor) family proteins. However, its significance remains
to be determined. Interestingly, HNF1 (hepatocyte
nuclear factor 1) also contains a POU-homeodomain,
while HNF3 alpha, which is also named FOXA1,c o n -
tains a fork head domain [31].
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the expression of other SOX family members but
up-regulates BEX1 and BEX2
We performed microarray analysis comparing SOX2
knockdown and MOCK transfected LN229 cells, and we
identified a total of 565 probes (489 known genes with
annotations) that were changed > 2 fold between SOX2
knockdown and SOX2-MOCK transfected LN229 cells
(Additional File 10). Array analysis confirmed that SOX2
expression was indeed decreased after SOX2 knockdown.
A d d i t i o n a l l y ,w ec o n f i r m e dt h ea r r a yd a t ab yR T - P C R
analysis of 13 randomly selected up-regulated genes after
SOX2 knockdown (BIRC3, NGFR, IL8, CRISPD2, CEBPA,
NFKB2, MAP3K14, NFKBIE, NR1H3, APIP, SOCS2,
PDGFRA, KIT, BEX1, BEX2, IL-6) (Figure. 3A).
Gene Ontology analysis of all GO categories revealed
that proteins belonging to these cellular locations
GO:0005576 extracellular region and GO:0005796 Golgi
lumen are enriched, and that proteins involved in the
GO:0042035 regulation of cytokine biosynthetic process
(Table 3). Indeed, we found that knockdown of SOX2
increased the expression of several cytokines including
IL6 and IL8, IL23, IL24 and IL32 (Table 4), and the
expression of two interleukin receptors-interleukin 7
receptor and interleukin 1 receptor-like 1. We also
found many interesting families of proteins that were
regulated by SOX2 by visual inspection of the gene list.
For example, we noticed that two other SOX family pro-
tein, SOX1 and SOX18, also exhibited reduced expres-
sion by more than 3 fold after SOX2 knockdown (Table 4).
We also found that many members of the protocadherins
including protocadherin 9, 10, beta 11, and gamma A3
and C3 were reduced after SOX2 knockdown. However,
the expression of protocadherin alpha 4 was increased
after SOX2 knockdown (Table 4). Protocadherin are a
large family of cadherin-related molecules that are highly
expressed in the brain and their expression appears to be
developmentally regulated [32].
The expression of many interesting gene families
were up regulated after SOX2 knockdown. For exam-
ple, we found that brain expressed genes BASP1
(brain abundant, membrane attached signal protein 1),
BEX1 ( b r a i ne x p r e s s e dX - l i n k e d1 )a n dBEX2 (brain
expressed X-linked 2) were up regulated after SOX2
knockdown (Table 4). We also found that knocking
down SOX2 also increase the expression of many
solute carrier family proteins including SLC2A3,
SLC3A2, SLC7A1, SLC14A1, SLC22A1 and SLC30A1.
These solute carrier proteins transport many important
solutes such as urea, glucose, organic cations, dibasic
and neutral amino acids, zinc, and cationic amino
acids (Table 4).
The gene regulated by SOX2 could be directly regu-
lated or indirectly regulated. By integrating the array
data with the ChIP-seq data, the directly targeted
genes of SOX2 can be inferred. We found 88 SOX2-
regulated genes whose promoters were bound by 127
SOX2 binding regions (Figure. 3D and Additional File 1).
Interesting genes include BCL2 (B-cell CLL/lymphoma
2) and BCL2 interacting protein 3 (BNIP3), four brain
and neuron expressed genes BASP1 (brain abundant,
membrane attached signal protein 1), NEDD4 (Neural
precursor cell expressed, developmentally down-regu-
lated 4), NRG1 (Neuregulin 1) and NEGR1 (Neuronal
growth regulator 1), two interleukins IL6 and IL8,t w o
protocadherins PCDH9 and PCDH10, RUNX1 (Runt-
related transcription factor 1, acute myeloid leukemia
1 oncogene), and three solute carrier proteins SLC3A2,
SLC7A1 and SLC30A1 (Additional File 11). The VENN
diagram also showed that 11 genes were common
SOX2 targets for GBM and ES cells and changed in
expression after SOX2 knockdown (Figure. 3D and
Table 5). They include EBF3 (early B-cell factor 3),
BASP1 (brain abundant, membrane attached signal
protein 1), SLC30A1 (solute carrier family 30 (zinc
transporter), member 1), and SLC3A2 (solute carrier
family 3, member 2). We speculate that these genes
may be involved in GBM stem cells. However, further
experimentations are necessary to understand the role
of these genes in glioma stem cells.
Table 2 Top known TFs binding sites in the SOX2
binding regions
Known TFs Number of occurrencies Percentage of total sites
AREB6_04 543 11.12
FOX_Q2 596 12.21
FOXD3_01 654 13.39
FOXJ2_01 506 10.36
FOXO1_01 519 10.63
GATA_C 524 10.73
GATA_Q6 647 13.25
GATA1_04 497 10.18
GR_Q6_01 491 10.06
HFH3_01 525 10.75
HNF1_Q6 530 10.85
HNF3_Q6 528 10.81
HNF3ALPHA_Q6 649 13.29
IRF1_Q6 702 14.38
OCT_Q6 594 12.16
OCT1_04 697 14.27
OCT1_06 554 11.35
OCT1_Q5_01 616 12.62
PIT1_Q6 571 11.69
POU1F1_Q6 633 12.96
TEF1_Q6 776 15.89
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in GBM cells
We also analyzed the effect of SOX2 on miRNAs using
next generation sequencing (Illumina). MicroRNA
sequencing is an efficient way to identify known and
novel microRNAs that are differentially expressed [33].
After miRNA sequencing and data analysis, we found
105 precursor microRNAs (corresponding to 95 mature
miRNAs) that were changed > 2 fold between SOX2
knockdown and SOX2-MOCK transfected LN229 cells
(Table 6 and Additional File 12). Six microRNAs includ-
ing miR-145, -143, -145*, -143*, -253-5p and miR-452,
Figure 3 Confirmation of SOX2 regulated genes and microRNAs. (A) Bar graph showing PCR confirmation of the array data of SOX2 gene
expression. SOX2-KO: SOX2 knockdown; MOCK, mock known down with negative control siRNAs. Y-axis, relative expression after normalizing the
MOCK control to value of 1; X-axis, gene symbols. (B). Bar graph showing PCR confirmation of the microRNA sequencing data. Y-axis, relative
expression after normalizing the MOCK control to value of 1; X-axis, microRNA names. (C). Western blot analysis showing the SOX2 expression
comparing microRNA 145 precursor mimics and a scrambled negative control. (D). A VENN diagram showing the overlaps of SOX2 targets in
GBM and ES cells, and the genes that changed expression (2 fold cutoff) after SOX2 knockdown in GBM cells.
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were down regulated when SOX2 was knocked down.
We picked 6 miRNAs to confirm the next generation
data using RT-PCR. We confirmed that miR-143 and
miR-145 were up regulated after SOX2 knockdown and
that miR-146a, -25, -20b and miR-9-1 were down regu-
lated after SOX2 knockdown (Figure. 3B).
Xu et al. showed that miR-145 targets SOX2 and
down regulates its expression in human embryonic stem
cells [34]. To see whether the same is true in GBM
cells, we transfected LN229 GBM cell with miR-145
mimics and we found that miR-145 also decreased
SOX2 expression in GBM cells (Figure. 3C). As knock-
ing down SOX2 up regulates miR145 in the RT-PCR
and next-generation sequencing data (Figure. 3B and
Table 6), this suggests that SOX2 itself down regulates
miR-145. Taken together, SOX2 down regulates miR-
145 and miR145 also down regulates SOX2, suggesting
that SOX2 and miR145 form a double-negative feedback
loop in GBM cells. We also checked to see whether
there are SOX2 binding regions in the proximity of
miR145 genomic locus. We found that there are no
SOX2 binding regions with significant P values (P <
0.01) in the close proximity of the miR145 locus. The
c l o s e s to n ei sa b o u t2 3k bf r o mt h em i R 1 4 5g e n o m i c
locus. This may suggest that the SOX2 feedback regula-
tion of miR145 is indirect, not resulting from direct
binding of the SOX2 to the miR145 genomic region.
Discussion
We applied ChIP-seq technology to identify global SOX2
binding regions in GBM cells. To our best knowledge,
this is the first global analysis of SOX2’s binding regions
in cancer cells. SOX2 encodes a member of the SRY-
related HMG-box (SOX) family of transcription factors.
We investigated SOX2’s global binding targets by ChIP-
Seq analysis, and found that SOX2 binding regions in
GBM cells are enriched for AT nucleotides with a con-
sensus sequence wwTGnwTw [w = A or T; its reverse
and complement strand wAwnCAww]. The mouse sox2
consensus motif in the mouse ES cells found by Chen
et al. has the sequence 5’-CATTGTT-3’ [26]. The simi-
larity lies in that both consensus sequences are AT rich
sequences with a core TG di-nucleotide flanked by AT
rich sequences. The difference may due to the fact that
they derived from different types of cells (ES vs. glioma)
and species (human vs. mouse).
The AT rich sequence we identified for SOX2 consen-
s u si sc o n s i s t e n tw i t hp r e v i o u sin vitro studies showing
that the HMG domain of SOX proteins binds to the
Table 3 Enriched GO terms in biological processes for SOX2 DEGs
GO CATEGORY TOTAL
GENES
CHANGED
GENES
ENRICHMENT LOG10
(p)
FALSE DISCOVERY
RATE
GO:0030935_sheet-forming_collagen 5 4 30.33 -5.64 0.00
GO:0042035_regulation_of_cytokine_biosynthetic_process 43 7 6.17 -3.93 0.04
GO:0005576_extracellular_region 561 30 2.03 -3.77 0.04
GO:0042107_cytokine_metabolic_process 48 7 5.53 -3.62 0.05
GO:0002376_immune_system_process 473 26 2.08 -3.51 0.05
GO:0042089_cytokine_biosynthetic_process 47 7 5.65 -3.68 0.05
GO:0044421_extracellular_region_part 392 24 2.32 -3.98 0.06
GO:0006952_defense_response 320 20 2.37 -3.51 0.06
GO:0005581_collagen 24 5 7.90 -3.46 0.07
GO:0042108_positive_regulation_of_cytokine_biosynthetic_process 29 5 6.54 -3.06 0.07
GO:0042226_interleukin-6_biosynthetic_process 8 3 14.22 -3.04 0.08
GO:0045408_regulation_of_interleukin-6_biosynthetic_process 8 3 14.22 -3.04 0.08
GO:0001525_angiogenesis 59 7 4.50 -3.06 0.08
GO:0005796_Golgi_lumen 7 3 16.25 -3.23 0.08
GO:0050926_regulation_of_positive_chemotaxis 7 3 16.25 -3.23 0.08
GO:0050927_positive_regulation_of_positive_chemotaxis 7 3 16.25 -3.23 0.08
GO:0032635_interleukin-6_production 17 4 8.92 -3.07 0.08
GO:0032675_regulation_of_interleukin-6_production 17 4 8.92 -3.07 0.08
GO:0042445_hormone_metabolic_process 57 7 4.66 -3.15 0.08
GO:0044420_extracellular_matrix_part 46 6 4.95 -2.91 0.08
GO:0032101_regulation_of_response_to_external_stimulus 62 7 4.28 -2.93 0.09
GO:0051093_negative_regulation_of_developmental_process 271 17 2.38 -3.08 0.09
GO:0050918_positive_chemotaxis 9 3 12.64 -2.87 0.09
GO:0009605_response_to_external_stimulus 415 22 2.01 -2.84 0.09
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a heptamer motif WWCAAAG (W = A or T) [35,36].
T h e r e f o r ew eh a v ei d e n t i f i e dA Tr i c hSOX2 specific
binding sequences. Before the development of ChIP-
chip or ChIP-Seq technologies, Mertin et al. determined
the DNA-binding properties of SOX9 using random oli-
gonucleotide selection assay [37] and they identified a
core sequence of an AT rich sequence AACAAT or
wwCAAw (w, A or T) for SOX9 binding. The HMG
domain in SOX family proteins forms an L-shaped mod-
ule composed of three helices that binds to DNA in the
minor groove. SOX proteins are categorized into Groups
A-G based on their sequence homology [38]. SOX2
belongs to Group A (also named SRY) and SOX9
belongs to group E [38]. The amino acid sequence iden-
tity of the HMG domain within the same group is high
a t> 9 0 % ,h o w e v e r ,t h ea m i n oa c i ds e q u e n c ei d e n t i t y
between distant groups decreases to ~60% [38]. A
sequence alignment revealed that SOX2 and SOX9 only
have about 61% amino acid sequence identity in the
HMG domain. The sequence variations may explain the
similar AT rich properties yet different consensus in
Table 4 Examples of SOX2 regulated genes and families
Gene Symbol ratio SOX2_KO/MOCK Description
SOX family
SOX1 0.32 SRY (sex determining region Y)-box 1
SOX18 0.50 SRY (sex determining region Y)-box 18
SOX2 0.30 SRY (sex determining region Y)-box 2
Brain-expressed
BASP1 3.52 brain abundant, membrane attached signal protein 1
BEX2 3.29 brain expressed X-linked 2
BEX1 4.81 brain expressed, X-linked 1
G protein-coupled receptor
GPR1 4.22 G protein-coupled receptor 1
GPR172B 2.07 G protein-coupled receptor 172B
GPR37 0.49 G protein-coupled receptor 37
Interleukins and their receptors
IL1RL1 2.48 interleukin 1 receptor-like 1
IL23A 2.60 interleukin 23, alpha subunit p19
IL24 5.73 interleukin 24
IL32 2.42 interleukin 32
IL6 10.25 interleukin 6 (interferon, beta 2)
IL7R 2.32 interleukin 7 receptor
IL8 2.22 interleukin 8
Solute carrier family
SLC14A1 4.81 solute carrier family 14 (urea transporter), member 1 (Kidd blood group)
SLC2A3 2.29 solute carrier family 2 (facilitated glucose transporter), member 3
SLC22A1 3.80 solute carrier family 22 (organic cation transporter), member 1
SLC3A2 2.07 solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2
SLC30A1 2.62 solute carrier family 30 (zinc transporter), member 1
SLC7A1 2.25 solute carrier family 7 (cationic amino acid transporter, y+ system), member 1
Protocadherin family
PCDH10 0.45 protocadherin 10
PCDH9 0.32 protocadherin 9
PCDHA4 2.20 protocadherin alpha 4
PCDHB11 0.38 protocadherin beta 11
PCDHGA3 0.49 protocadherin gamma subfamily A, 3
PCDHGC3 0.43 protocadherin gamma subfamily C, 3
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functional binding assays including mutagenesis and
footprinting analysis will be needed to confirm the bind-
ing activities and specificities. Further experimentation
is therefore warranted.
It was a surprise to find that about one quarter of
genes regulated by SOX2 encompass important GO
c a t e g o r i e s :1 9 6o u to f7 9 2g e n e s( a b o u t2 5 % )w e r e
found to have signal transducer activity (GO:0004871),
101 of 410 belong to transmembrane receptor genes
(about 25%) (GO: 0004888), and 92 of 365 are kinase
genes (about 25%) (GO:0016301). Signal transducer,
receptor and kinase genes are important genes that play
an essential role in cellular functions and therefore it is
not surprising that SOX2 is an essential gene that plays
important roles in development and in carcinogenesis.
We found that BEX1 (brain expressed X-linked 1) and
BEX2 (brain expressed X-linked 2) were up regulated
after SOX2 knockdown (Table 4). We have previously
shown that BEX1 and BEX2 are silenced in GBM tumor
specimens and exhibited extensive promoter hyper-
methylation [39]. We demonstrated by in vitro and in a
xenograft mouse model that BEX1 or BEX2 possess
tumor suppressor activity [39]. Our data suggested that
SOX2 might down regulate BEX1 and BEX2 expression,
reducing their tumor suppressor activities and thus pro-
moting carcinogenesis. However, we did not find SOX2
binding regions in the BEX1 and BEX2 gene loci, sug-
gesting the down regulation was properly an indirect
effect of SOX2 knockdown.
We found that SOX2 also regulates the expression of
SOX family protein SOX1 and SOX18 (Table 4). SOX1
plays roles in neural determination and differentiation
[40] and is a neural stem cell marker [41]. Bylund et al.
showed that sox1, sox2 and sox3 are the transcription fac-
tors that keep neural cells undifferentiated by counteract-
ing the activity of proneural proteins [42]. However, the
role of SOX1 in GBM has not yet been studied. SOX18
plays important roles in blood vasculature formation [43].
Young et al. assessed the effects of disrupted SOX18
function on MCF-7 human breast cancer and human
umbilical vein endothelial cell (HUVEC) proliferation by
measuring BrdU incorporation and by MTT assay, cell
migration using Boyden chamber assay, and capillary
t u b ef o r m a t i o ni nv i t r o[ 4 4 ] .T h e ys h o w e dt h a to v e r
expression of wild-type SOX18 promoted capillary tube
formation of HUVECs in vitro, whereas expression of
dominant-negative SOX18 impaired tube formation of
HUVECs [44]. Therefore, SOX18 is a potential target for
antiangiogenic therapy of human cancers. The role of
SOX18 in GBM has not been studied. Taking together,
SOX2 could act through SOX1 and SOX18, and thus play
roles in both maintaining stem cell properties of glioma
cells and forming tumor vasculature in gliomas, which
are two major obstacles preventing us from treating these
tumors effectively.
By microRNA sequencing we determined that levels of
105 precursor microRNAs (corresponding to 95 mature
miRNAs) are altered in response to SOX2 knockdown
(Table 6 and Additional File 12). We showed that SOX2
could down regulate the expression of miR-143 and
miR-145. miR-145 was shown to be down regulated in
several cancers such as colon cancers [45] and prostate
cancers [46], and miR-143 was shown to be down regu-
lated in colon cancers [47] and bladder cancers [48].
The relationship of miR-143 and miR-145 and GBM has
not been studied and is worth future investigation.
We further demonstrated that SOX2 and miR-145 form
a double-negative regulation loop in GBM cells (Figure.
4A). Double-negative feedback loop involving microRNAs
and their targets have been observed previously [49,50]. A
double-negative feedback mechanism has been proposed
as a mechanism to form bistability in cellular states. John-
ston et al. demonstrated that the stability and irreversibil-
ity of the terminal differentiated state of neuronal cells is
ensured by a double-negative feedback loop between two
microRNAs lsy-6 and mir-273 and their transcription fac-
tor targets in the nematode Caenorhabditis elegans [50].
Table 5 Common SOX2 targets of human GBM and ES cells that changed expression after SOX2 knockdown
Gene Symbol Mock/SOX2_KO ratios Description
ALCAM 2.02 activated leukocyte cell adhesion molecule
BASP1 0.28 brain abundant, membrane attached signal protein 1
BCAT1 0.38 branched chain aminotransferase 1, cytosolic
COL12A1 2.17 collagen, type XII, alpha 1
CTH 0.37 cystathionase (cystathionine gamma-lyase)
EBF3 2.03 early B-cell factor 3
KLF5 0.49 Kruppel-like factor 5 (intestinal)
ONECUT1 0.48 one cut domain, family member 1
PTHLH 0.34 parathyroid hormone-like hormone
SLC30A1 0.38 solute carrier family 30 (zinc transporter), member 1
SLC3A2 0.48 solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2
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generation sequencing
precursor miRNA
ID
mature miRNA
ID
MOCK/SOX2
KO
P value
hsa-mir-106a hsa-miR-106a 17.89 1.94E-68
hsa-mir-106a hsa-miR-106a* 20.50 2.41E-06
hsa-mir-106b hsa-miR-106b* 2.68 2.30E-05
hsa-mir-106b hsa-miR-106b 2.55 9.03E-05
hsa-mir-10b hsa-miR-10b 2.70 1.09E-05
hsa-mir-125b-1 hsa-miR-125b 2.80 2.79E-06
hsa-mir-125b-1 hsa-miR-125b-1* 2.62 6.78E-05
hsa-mir-125b-2 hsa-miR-125b 2.80 2.75E-06
hsa-mir-1268 hsa-miR-1268 2.85 5.28E-06
hsa-mir-1271 hsa-miR-1271 3.44 0.000102818
hsa-mir-1287 hsa-miR-1287 6.63 6.21E-17
hsa-mir-1301 hsa-miR-1301 3.60 5.03E-06
hsa-mir-1305 hsa-miR-1305 3.28 2.17E-05
hsa-mir-1307 hsa-miR-1307 4.36 6.38E-16
hsa-mir-130b hsa-miR-130b* 3.97 2.19E-11
hsa-mir-135b hsa-miR-135b* 5.26 8.40E-19
hsa-mir-135b hsa-miR-135b 5.09 2.86E-17
hsa-mir-140 hsa-miR-140-3p 8.69 2.82E-41
hsa-mir-140 hsa-miR-140-5p 7.93 4.29E-37
hsa-mir-143 hsa-miR-143 0.02 3.04E-182
hsa-mir-143 hsa-miR-143* 0.05 2.41E-72
hsa-mir-145 hsa-miR-145 0.02 1.99E-132
hsa-mir-145 hsa-miR-145* 0.03 4.74E-113
hsa-mir-146a hsa-miR-146a 17.38 1.05E-73
hsa-mir-146a hsa-miR-146a* 11.40 7.59E-07
hsa-mir-149 hsa-miR-149 4.27 3.27E-14
hsa-mir-15b hsa-miR-15b* 3.18 3.05E-05
hsa-mir-17 hsa-miR-17 3.28 2.85E-09
hsa-mir-187 hsa-miR-187 9.55 1.40E-09
hsa-mir-188 hsa-miR-188-5p 4.83 2.82E-08
hsa-mir-18a hsa-miR-18a 3.46 1.76E-09
hsa-mir-18b hsa-miR-18b 21.77 1.55E-47
hsa-mir-190 hsa-miR-190 2.78 2.00E-05
hsa-mir-196a-1 hsa-miR-196a 2.58 5.85E-05
hsa-mir-196a-2 hsa-miR-196a 2.55 9.28E-05
hsa-mir-1977 hsa-miR-1977 0.32 4.88E-07
hsa-mir-200c hsa-miR-200c 2.63 5.38E-05
hsa-mir-204 hsa-miR-204 38.20 4.44E-83
hsa-mir-20a hsa-miR-20a 3.03 1.10E-07
hsa-mir-20b hsa-miR-20b 24.84 1.62E-88
hsa-mir-20b hsa-miR-20b* 16.86 4.09E-28
hsa-mir-217 hsa-miR-217 6.54 1.10E-10
hsa-mir-224 hsa-miR-224* 0.13 4.22E-18
hsa-mir-2276 hsa-miR-2276 11.25 2.06E-15
hsa-mir-25 hsa-miR-25 2.92 5.28E-07
hsa-mir-28 hsa-miR-28-3p 2.70 1.25E-05
hsa-mir-30b hsa-miR-30b 4.91 1.20E-19
hsa-mir-30d hsa-miR-30d 4.80 2.04E-19
hsa-mir-30d hsa-miR-30d* 4.79 8.38E-12
hsa-mir-320a hsa-miR-320a 2.54 0.000106251
Table 6 SOX2 regulated miRNAs identified by next
generation sequencing (Continued)
hsa-mir-330 hsa-miR-330-5p 3.90 5.23E-06
hsa-mir-338 hsa-miR-338-5p 42.70 2.78E-75
hsa-mir-338 hsa-miR-338-3p 32.33 6.56E-64
hsa-mir-339 hsa-miR-339-5p 2.75 4.52E-05
hsa-mir-340 hsa-miR-340* 4.53 5.95E-10
hsa-mir-361 hsa-miR-361-3p 2.66 6.29E-05
hsa-mir-362 hsa-miR-362-5p 4.32 8.19E-13
hsa-mir-363 hsa-miR-363 21.08 2.70E-82
hsa-mir-423 hsa-miR-423-3p 3.19 1.05E-08
hsa-mir-452 hsa-miR-452 0.20 4.36E-59
hsa-mir-454 hsa-miR-454* 7.09 8.55E-13
hsa-mir-454 hsa-miR-454 2.79 7.68E-05
hsa-mir-484 hsa-miR-484 3.32 1.74E-08
hsa-mir-500 hsa-miR-500* 4.18 2.46E-14
hsa-mir-501 hsa-miR-501-3p 6.15 2.77E-19
hsa-mir-501 hsa-miR-501-5p 5.17 6.25E-11
hsa-mir-502 hsa-miR-502-3p 4.19 9.80E-11
hsa-mir-514-1 hsa-miR-514 9.25 0.000108265
hsa-mir-514-2 hsa-miR-514 9.25 0.000108265
hsa-mir-514-3 hsa-miR-514 9.25 0.000108265
hsa-mir-532 hsa-miR-532-5p 4.74 2.71E-18
hsa-mir-532 hsa-miR-532-3p 3.72 1.47E-07
hsa-mir-548d-1 hsa-miR-548d-5p 3.52 2.17E-08
hsa-mir-548d-2 hsa-miR-548d-5p 3.45 3.03E-08
hsa-mir-548n hsa-miR-548n 3.84 2.66E-08
hsa-mir-573 hsa-miR-573 5.67 6.41E-06
hsa-mir-574 hsa-miR-574-5p 4.68 8.73E-18
hsa-mir-577 hsa-miR-577 14.88 6.79E-60
hsa-mir-584 hsa-miR-584 9.12 1.41E-42
hsa-mir-585 hsa-miR-585 46.00 2.35E-14
hsa-mir-589 hsa-miR-589* 3.76 3.23E-08
hsa-mir-589 hsa-miR-589 2.83 2.95E-06
hsa-mir-590 hsa-miR-590-3p 3.15 6.09E-06
hsa-mir-592 hsa-miR-592 24.45 1.71E-52
hsa-mir-615 hsa-miR-615-3p 3.79 5.88E-09
hsa-mir-616 hsa-miR-616 3.26 6.21E-05
hsa-mir-626 hsa-miR-626 0.12 2.40E-10
hsa-mir-652 hsa-miR-652 3.99 1.57E-12
hsa-mir-660 hsa-miR-660 4.27 1.17E-10
hsa-mir-671 hsa-miR-671-5p 2.73 8.59E-06
hsa-mir-671 hsa-miR-671-3p 2.83 5.90E-05
hsa-mir-760 hsa-miR-760 10.74 1.39E-27
hsa-mir-873 hsa-miR-873 11.50 1.21E-14
hsa-mir-877 hsa-miR-877 4.22 2.51E-13
hsa-mir-889 hsa-miR-889 0.16 3.89E-05
hsa-mir-9-1 hsa-miR-9 10.74 2.37E-50
hsa-mir-9-1 hsa-miR-9* 11.87 3.43E-35
hsa-mir-9-2 hsa-miR-9 10.74 2.39E-50
hsa-mir-9-2 hsa-miR-9* 11.87 3.43E-35
hsa-mir-9-3 hsa-miR-9 10.74 2.37E-50
hsa-mir-9-3 hsa-miR-9* 11.06 2.66E-35
Fang et al. BMC Genomics 2011, 12:11
http://www.biomedcentral.com/1471-2164/12/11
Page 12 of 17A positive-feedback loop or double-negative feedback
loops can convert graded inputs into switch-like, irreversi-
ble responses [51]. Such a system will be “bistable” as the
system exists almost exclusively in one of two possible
states. Bistability has been shown in several signal trans-
duction and transcriptional regulatory events such as the
p42 mitogen-activated protein kinase and c-Jun amino-
terminal kinase pathways in Xenopus oocytes [51]. For a
bistable system with two components A and B, the system
will toggle between two stable states: one with A on and B
off and one with B on and A off. For example, for the
SOX2 and miR-145 bistable system, the system can be on
SOX2 on, miR-145 off state or SOX2 off, miR-145 on state
(Figure. 4B). Further experimentation will be necessary to
analyze in detail the two cellular states for the SOX2-
miR145 double-negative feedback loop in GBM cells.
Conclusion
We have comprehensively characterized the SOX2
response program by integrated analysis using several
advanced technologies including ChIP-seq, microarrays
and microRNA sequencing. The datasets of ChIP-seq,
microarrays and microRNA sequencing of SOX2
response program, which, to our best knowledge, are the
first datasets of SOX2 in cancers, will be useful resources
for the research community. Furthermore, the insights
we gained from our integrated analysis further our
understanding of the roles of SOX2 in carcinogenesis.
Methods
Cell culture and functional assays
LN229 cells were obtained from the American Type
Culture Collection (Manassas, VA) and maintained in
DMEM with 10% fetal bovine serum. Cell proliferation
was analyzed using the MTT assay kits (Millipore, Bill-
erica, MA) according to the manufacturer’sp r o t o c o l .
For Soft agar colony formation assay, cells were trypsi-
nized and counted. 10,000 cells were seeded in six-well
plates. After 2 weeks of growth, colonies with a diameter
greater than 4 mm were counted. Experiments were
performed in quadruplicates [39].
Chromatin immunoprecipition (ChIP) - Sequencing
About 3 × 10
6 LN229 cells were used for chromatin
immunoprecipition (ChIP) assay, carried out according
to the manufacturer’s instructions (Millipore, EZ-Magna
ChIP™ A). Antibodies used for ChIP included SOX2
(ab59776, Abcam Inc.) and IgG (sc-2027, Santa Cruz
Biotehnology Inc.). For ChIP, SOX2 antibody was tested
for its specificity and specific band was found (Figure
1A). ChIP assay was performed using the ChIP kit
(Upstate Biotechnology, Lake Placid, NY) according to
the manufacturer’s protocol. Briefly, cells were cross-
linked by adding fresh formaldehyde to cell culture
medium to a final concentration of 1%. Fixation was
monitored at 37°C for 10 min. The fixed cells were re-
suspended in the lysis buffer. Nuclei were collected by
centrifugation at 2000 × g, and resuspended in the
nuclei lysis buffer. Samples were sonicated on ice to the
length of 200-500 base pairs. 5 μg antibody and 50 μl
Dynal protein G beads were incubated for 2 hours at
4°C. Sonicated chromatin were incubated with the pro-
tein G- antibody complex overnight at 4°C. Precipitated
immunocomplex was treated with proteinase K for
2 hours at 65°C, and DNA was purified Qiagen Qiaquick
PCR purification kit. ChIP DNA end repairing, adaptor
ligation, and amplification were performed as described
earlier [23]. Fragments of about 200 bp (without linkers)
were isolated from agarose gel and used for sequencing
using the Illumina 2 G genetic analyzer. Illumina data
analysis pipeline was performed as described [23].
Figure 4 The double negative feedback loop of SOX2 and miR-
145. (A) An illustrative drawing showing the double negative
feedback loop of SOX2 and microRNA 145. Negative signs and
upside down T line drawing indicate inhibitive action. Both SOX2
and miR-145 can receive separate input signals (signal A or signal
B). (B) Theoretical bistable output of this double negative feedback
loop. Depending on the strength of the input signal A or B, the
system could toggle between two stable states: the signal A-SOX2
or the signal B-miR-145 states.
Table 6 SOX2 regulated miRNAs identified by next
generation sequencing (Continued)
hsa-mir-92a-1 hsa-miR-92a 3.38 5.65E-10
hsa-mir-92a-2 hsa-miR-92a 3.35 8.85E-10
hsa-mir-93 hsa-miR-93 3.46 1.43E-10
hsa-mir-942 hsa-miR-942 3.43 3.82E-07
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associated annotations were used for all analysis.
Sequence reads that map to multiple sites in the human
genome were removed. To identify SOX2 binding peaks,
we used SISSRs (Site Identification from Short Sequence
Reads) (http://www.rajajothi.com/sissrs/) [25] with
default parameters with E-value is set to 10, P value set
to 0.001. SOX2 ChIP-seq as positive and IgG control
ChIP-seq data as negative input.
To calculate the distance to the TSS start site, annota-
tions from the UCSC (hg18) were used. We also took
into consideration the direction of the strand when we
calculated the distance to TSS. As the SOX2 binding
r e g i o n si sa l w a y sr e c o r d e do nt h ep o s i t i v es t r a n d s ,f o r
genes mapped to the positive strand, the distance is the
end position of the SOX2 binding region minus the TSS
start position; for genes mapped to the negative strand,
the distance is the TSS start position minus the SOX2
binding region start position.
Validation of ChIP-seq datasets by ChIP-qPCR
We selected a list of binding peaks for validation using
quantitative real-time PCR. The primers were listed in
the Additional File 13. Three replicates were run. Real-
time PCR was performed using the SYBR® Green (Invi-
trogen) dye detection method on ABI PRISM 7900 HT
Sequence Detection System under default conditions:
95°C for 10 min, and 35 cycles of 95°C for 15 s and
55°C for 1 min. Comparative Ct method was used for
quantification of the transcripts.
Gene Ontology Analysis
High-Throughput GoMiner [52] was used to find statis-
tically over represented Gene Ontology (GO) terms. GO
terms of all evidence levels and categories were used for
the analysis. The algorithm used by the High-through-
put GoMiner [52], which is the one-sided Fisher exact p
value corrected for multiple comparisons, was used to
calculate the FDR (false discovery rate). To identify over
represented GO terms in the 3162 unique SOX2 targets
in GBM cells versus the 817 unique SOX2 targets in
human ES cells, we GSEA (http://www.broadinstitute.
org/gsea/index.jsp). The parameters used were: 1000
permutations using the C5 gene sets (GO gene sets), the
diff_of_classes algorithm as metric for ranking genes,
weighted enrichment statistic, minimum gene set size of
3. Other parameters were set as default.
Motif scanning and identification
To identify novel motifs, SOX2 binding regions identi-
fied by ChIP-seq were extended to 100 bp 5’ and 3’ and
the sequences were retrieved in FASTA format. The
sequences were first subjected to the RepeatMask pro-
gram (http://www.repeatmasker.org/) to mask all human
repeats. We used the MotifSampler to find over-
expressed motifs in the SOX2 binding regions with the
default parameters. The over represented sequences
were used as input for the Weblog program (http://
weblogo.berkeley.edu/) [53] to display the consensus
sequence graphically. For a systematic search for all
potential transcription binding sites, we used the Motifs-
canner software (http://bioinformatics.psb.ugent.be/
webtools/plantcare/html/Motif_Sampler.html). Human
upstream sequences from EPD (The Eukaryotic Promo-
ter Database) (epd_homo_sapiens_499_chromgenes_-
non_split_3.bg) were downloaded from the motif
scanner web site and used as the background model.
The human subset of the Transfac professional 7.0
PWM matrices was used. Matched TF matrices with
likelihood ratios (LR) of 500 or higher were tabulated
and their frequencies calculated.
Small interfering RNA transfection
SOX2 SiRNAs (Ambion Inc) were used for transient
knockdown of SOX2. The SiRNA sequences are: s13295,
sense sequence AGUGGAAACUUUUGUCGGATT and
antisense sequence, UCCGACAAAAGUUUCCACUCG;
S13296, sense sequence ACCAGCGCAUGGACAGU-
UATT and anti-sense sequence UAACUGUCCAUGCG-
CUGGUTC. LN229 cells were seeded into six well
plates, cultured overnight and transfected with SOX2
SiRNAs at a final concentration of 100 nM using Tran-
sIT-OT1 (Mirus Bio LLC, Madison WI) according to
the manufacturer’s instructions. At 72 hours after tans-
fection, cells were harvested for western blot analysis
and for microarray analysis.
Microarray analysis
The Applied Biosystems’ microarray platform was used
using the standard array hybridization protocol as we
described previously [39]. The ABI arrays contain
31,700 60-mer oligonucleotide probes representing
29,098 individual human genes. Two biological repli-
cates were performed including cell transfection and
microarray analysis. GeneSpring program were used to
analyze the array data. The raw signal intensities indivi-
dual probes were combined (averaged) based on Celera’s
Gene ID (ABI’s annotation table), and then imported
into the GeneSpring program, and data from individual
chip were normalized per chip with 75% percentile and
normalized per gene by median. To filter out those
lowly expressed genes across all chips, only arrays data
with a signal to noise (S/N) ratio of > 3 in one of the
arms (SOX2 Knockdown or mock knockdown) were
used for analysis. Two biological replicates were per-
formed. The normalized data for the replicates were
averaged for each gene. To identify differentially
expressed genes, a two fold cutoff value was used.
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The human genome build hg18 and its associated annota-
tions were used for all analysis. The SOX2 binding regions
identified by ChIP-seq (Table S2) was annotated with the
genome annotation of hg18 for their associated genes
using the nearest gene within 50 kb of the TSS (transcrip-
tion start site) or TES (transcription end site). As the pub-
lished human ChIP-Chip data in human embryonic stem
cells [27] was annotated in 2005 with human genome
hg17 when the paper was published, the annotation was
outdated. We first converted the SOX2 binding regions
coordinates (Table S3 of the Boyer’s paper) into the hg18
coordinates using the tool liftover (http://genome.ucsc.
edu/cgi-bin/hgLiftOver). We re-annotated the human ES
SOX2 binding regions with hg18 annotations using the
chromosomal coordinates with the same criteria as we
used for the GBM SOX2 ChIP-seq data. There were 1,075
human ES SOX2 binding regions that could be annotated
with nearby genes. To identify overlapping genes between
SOX2 ChIP-seq and the microarray data, we used the gene
symbols from the HUGO gene nomenclature committee
(http://www.genenames.org/) to compare the two lists. To
compare the human ChIP-seq data with the sox2 targets
that were identified in mouse ES cells [26], we used the
homologene table for human and mouse from NCBI
(http://www.ncbi.nlm.nih.gov/homologene) to identify the
human homologues for the mouse sox2 targets and then
used the human homologues to compare with the human
SOX2 ChIP-seq data.
RNA isolation and Small RNA sequencing
RNA was isolated from cells using mirVana™ miRNA Iso-
lation Kit (Ambion, Austin, TX) according to the manu-
facturer’s instructions. Sequencing library preparation
was carried out according to Illumina mirna sample pre-
paration protocol. Small RNA samples were sequenced
using GA2 sequencer (Illumina)
For data analyses, Solexa adapters were first trimmed
from raw sequences using custom Perl scripts, and the
trimmed sequences were then aligned to known human
miRNAs precursors (miRBase release 14) using miREx-
press [54]. The -t parameter (alignment identity between
query and reference sequences) for miRExpress was set
to be 0.9. The expression abundance of corresponding
miRNAs were counted by miRExpress and normalized
by the counts of trimmed sequences in the library and
used for further analysis.
Differentially expressed miRNAs were identified by
statistics analysis using edgeR package from bioconduc-
tor[55]. The top differentially expressed ones were clus-
tered by MeV [56,57].
Validation of miRNAs expression by RT-PCR
We selected a list of miRNAs for validation using quan-
titative real-time PCR. The primers were available upon
request. Three replicates were run. Real-time PCR was
performed using the SYBR® Green (Invitrogen) dye
detection method on ABI PRISM 7900 HT Sequence
Detection System under default conditions: 95°C for
30 s, and 40 cycles of 95°C for 15 s and 60°C for 20 s.
Comparative Ct method was used for quantification of
the transcripts.
Transfection of microRNA
microRNA-145 precursor mimics was obtained from
Ribobio company (Guanzhou China). A scrambled pre-
cursor with no homology to the human genome was
used as controls. LN229 cells were transfected with the
precursor mimics by lipofectamine 2000 (Invitrogen).
Data access
The array data for SOX2 knockdown and control data
from this study have been submitted to Gene Expression
Omnibus (GEO) under accession No.GSE23839. The
SOX2 ChIP-seq data from this study have been sub-
mitted to Gene Expression Omnibus (GEO) under
accession No. GSE23795.
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